Opioid Addiction Risk Transparency Act
This bill amends the Federal Food, Drug, and Cosmetic Act to authorize the Food and Drug Administration to require a communication plan that is part of a medication's risk evaluation and mitigation strategy to include informing health care providers about the meaning of terms related to properties of the medication described in the labeling.
Take Action
Your position
Add a comment
to comment on this bill.
Annotate the text
Highlight any passage on the Summary or Full Text tab to attach a note. Annotations appear on the Annotations tab.